DBVT

DBV Technologies ADR

10.45

Nov 06 • 3:59 PM ET +0.65 (6.63%)

10.45

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology France Small NASD

Peers: PHVS ACRS UPB EVMN ALMS ARQT ANAB CNTB VRCA JSPR

| Held by: APIE

Scroll to Statements

Index	-
Market Cap	656.68M
Enterprise Value	513.18M
Income	-207.33M
Sales	0.00M
Book/sh	2.36
Cash/sh	2.64
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	125
IPO	Oct 22, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.42
P/C	3.96
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.24
Current Ratio	3.24
Debt/Eq	0.15
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-3.02
EPS next Y	-0.70
EPS next Q	-0.23
EPS this Y	-8.03%
EPS next Y	38.29%
EPS next 5Y	45.77%
EPS past 3/5Y	5.33% 18.68%
Sales past 3/5Y	- -
EPS Y/Y TTM	42.37%
Sales Y/Y TTM	-
EPS Q/Q	40.80%
Sales Q/Q	-
Earnings	Oct 28 AMC
EPS/Sales Surpr.	46.15% 220.00%

Insider Own	13.77%
Insider Trans	-0.01%
Inst Own	26.00%
Inst Trans	12.53%
ROA	-127.24%
ROE	-205.84%
ROIC	-133.50%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	8.29%
SMA50	-5.54%
SMA200	-37.32%
Trades

Shs Outstand	62.84M
Shs Float	54.18M
Short Float	1.61%
Short Ratio	2.37
Short Interest	0.87M
52W High	26.18 -60.09%
52W Low	8.63 21.09%
Volatility	8.26% 6.23%
ATR (14)	0.68
RSI (14)	52.63
Beta	-0.85
Rel Volume	0.57
Avg Volume	368.33K
Volume	210,655

Perf Week	10.12%
Perf Month	9.42%
Perf Quarter	-26.77%
Perf Half Y	-47.03%
Perf YTD	-45.49%
Perf Year	-25.57%
Perf 3Y	4.50%
Perf 5Y	-65.28%
Perf 10Y	-96.99%
Recom	1.00
Target Price	41.92
Prev Close	9.80
Price	10.45
Change %	6.63%

Consensus

Strong Buy

Avg. Price Target

$41.92

Implied Upside

+301.1%

Analysts11incl. previous ratings

Rating Distribution5 Buy · 4 Hold · 2 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Dec 15, 2025	Initiated	CCantor Fitzgerald	Overweight	$42	+301.9%
Dec 03, 2025	Initiated	GGuggenheim	Buy	$35	+234.9%
May 29, 2025	Resumed	GGoldman	Sell	$7.25	-30.6%
Jan 04, 2023	Upgrade	SSociete Generale	Hold → Buy
Dec 16, 2022	Downgrade	GGoldman	Neutral → Sell
May 10, 2022	Downgrade	GGoldman	Buy → Neutral	$6 → $1.50	-85.6%
Sep 14, 2021	Upgrade	SSociete Generale	Hold → Buy
Jan 22, 2021	Downgrade	SSociete Generale	Hold → Sell
Nov 02, 2020	Upgrade	SSociete Generale	Sell → Hold
Aug 06, 2020	Downgrade	SSociete Generale	Buy → Sell
Aug 05, 2020	Reiterated	HH.C. Wainwright	Buy	$25 → $14	+34.0%
Mar 17, 2020	Downgrade	SStifel	Buy → Hold	$18 → $6	-42.6%
Jan 09, 2020	Upgrade	SStifel	Hold → Buy	$10 → $18	+72.2%
Dec 16, 2019	Initiated	CCitigroup	Buy
Sep 05, 2019	Resumed	MMorgan Stanley	Equal-Weight
Jun 17, 2019	Initiated	GGoldman	Buy
Dec 20, 2018	Downgrade	SStifel	Buy → Hold
Dec 20, 2018	Downgrade	JJefferies	Buy → Hold
Dec 20, 2018	Downgrade	BBofA/Merrill	Buy → Underperform
Dec 20, 2018	Downgrade	BBarclays	Overweight → Equal Weight

Nov-02-26 04:30PM	DBV Technologies to Participate in Upcoming November Investor Conferences (GlobeNewswire) +11.71%
Oct-29-26 05:15AM	DBV Technologies shares slide 8% on going-concern warning, wider Q3 loss (Investing.com)
Oct-28-26 04:47PM	DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update (GlobeNewswire) +5.19%
Oct-27-26 08:34PM	DBV Technologies Must Prove Its Peanut Patch BLA Landed On Schedule As Shares Slump (Earnings Whispers)
04:30PM	DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 (GlobeNewswire)
06:29PM	Loading…
Sep-29-26 06:29PM	DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 Years (GlobeNewswire)
Sep-03-26 04:32PM	DBV Technologies to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Sep-02-26 05:55PM	Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (GlobeNewswire)
Jul-30-26 05:40PM	DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq (GlobeNewswire)
Jul-17-26 05:00PM	DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales (GlobeNewswire)
Jul-16-26 04:10PM	DBV Technologies Announces the Filing of its 2026 Half-Year Report ? Conditions for Accessing or Consulting the Report (GlobeNewswire) -5.41%
04:01PM	DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update (GlobeNewswire)
Jul-14-26 04:30PM	DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 (GlobeNewswire)
Jul-06-26 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire) +11.15%
Jun-29-26 04:00PM	DBV Technologies Provides BLA Submission Update for the VIASKIN Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing (GlobeNewswire)
04:30PM	Loading…
Jun-23-26 04:30PM	DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index (GlobeNewswire)
Jun-09-26 07:00AM	DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
Jun-08-26 04:35PM	DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026 (GlobeNewswire)
Jun-05-26 04:30PM	DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire) -5.63%
Jun-03-26 04:31PM	Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026 (GlobeNewswire)
04:30PM	DBV Technologies Announces the Results of its 2026 Combined General Meeting (GlobeNewswire)
Jun-02-26 07:40PM	DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy (GlobeNewswire)
May-13-26 04:30PM	Combined General Meeting of June 3, 2026 (GlobeNewswire)
May-12-26 04:30PM	DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq (GlobeNewswire)
Apr-30-26 04:30PM	DBV Technologies Reports First Quarter 2026 Financial Results (GlobeNewswire) -5.38%
Apr-14-26 08:11PM	Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know (Quartz)
Apr-02-26 04:30PM	Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 (GlobeNewswire)
02:20AM	Scancell CFO to step down as cancer immunotherapy developer names interim replacement (Proactive)
Mar-26-26 05:19PM	DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document (GlobeNewswire)
05:06PM	DBV Technologies Reports Full Year 2025 Financial Results and Business Update (GlobeNewswire)
04:30PM	Loading…
Mar-24-26 04:30PM	DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review (GlobeNewswire)
Mar-04-26 04:30PM	DBV Technologies to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Mar-03-26 04:30PM	Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 (GlobeNewswire) -5.94%
Feb-28-26 02:25PM	DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting (GlobeNewswire)
Feb-13-26 07:13AM	DBV Technologies Details Viaskin Peanut BLA Timeline, VITESSE Data and Launch Plans at Conference (MarketBeat)
Feb-10-26 04:30PM	DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting (GlobeNewswire) +7.11% -5.04%
Feb-09-26 04:30PM	DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit (GlobeNewswire)
Feb-05-26 04:30PM	Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026 (GlobeNewswire) -8.33%
Jan-16-26 06:11PM	DBV Technologies Announces 166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing (GlobeNewswire) +10.53%
Jan-12-26 04:00PM	Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 (GlobeNewswire) +5.41% -5.02%
Jan-07-26 04:00PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire) +8.18% -5.50%
Jan-05-26 04:00PM	Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025 (GlobeNewswire) -10.81%
Dec-21-25 07:31AM	H.C Wainwright and Citizens Raise PT on DBV Technologies (DBVT) Following Phase 3 VITESSE Trial Result (Insider Monkey)
Dec-17-25 04:01PM	DBV Launches, Up As Much As 46%, On A New Approach To Peanut Allergy (Investor's Business Daily) +25.42%
08:42AM	These Stocks Are Moving the Most Today: Tesla, Warner Bros., Lennar, DBV Technologies, Jabil, Nucor, Micron, and More (Barrons.com)
07:27AM	DBV to make new approval bid for VIASKIN Peanut on Phase III trial (Clinical Trials Arena)
Dec-16-25 04:05PM	DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years (GlobeNewswire)
Dec-15-25 09:16AM	Here Are Mondays Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More (24/7 Wall St.)
Dec-03-25 09:15AM	Here Are Wednesdays Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendys and More (24/7 Wall St.)
Dec-02-25 04:00PM	Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 (GlobeNewswire)
Nov-11-25 11:50PM	DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years (GlobeNewswire)
Nov-04-25 04:30PM	DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Nov-03-25 04:30PM	DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer (GlobeNewswire)
04:25PM	Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (GlobeNewswire)
Oct-31-25 09:40AM	Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-30-25 04:30PM	DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors (GlobeNewswire) -7.36%
03:00AM	DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting (GlobeNewswire)
Oct-29-25 06:47PM	DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq (GlobeNewswire)
Oct-28-25 04:25PM	DBV Technologies Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-17-25 09:16AM	Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength? (Zacks)
Oct-06-25 05:02PM	DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq (GlobeNewswire) +7.15%
Sep-23-25 05:04AM	New Strong Sell Stocks for September 23rd (Zacks)
Sep-18-25 04:30PM	DBV Technologies Announces Resignation of Board Member (GlobeNewswire)
Sep-05-25 04:30PM	DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq (GlobeNewswire)
Sep-03-25 04:30PM	DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-01-25 04:05PM	Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 (GlobeNewswire) +5.76%
Jul-29-25 04:17PM	DBV Technologies announces filing of 2025 Half-Year Report ? Conditions for accessing or consulting the Report (GlobeNewswire)
04:08PM	DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results (GlobeNewswire)
Jul-28-25 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Jul-24-25 07:40AM	Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last? (Zacks)
Jul-22-25 04:30PM	DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer (GlobeNewswire)
Jul-09-25 07:20AM	DBV Technologies Begins Pivotal Peanut Allergy Study, Aims for 2026 FDA Submission. (Insider Monkey)
Jun-25-25 04:15PM	DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 - 3 Years Old (GlobeNewswire) +6.60%
Jun-23-25 09:40AM	Is CoreCard (CCRD) Stock Outpacing Its Business Services Peers This Year? (Zacks) -8.94%
09:40AM	Are Utilities Stocks Lagging E.ON (EONGY) This Year? (Zacks)
09:40AM	Are Transportation Stocks Lagging Euroseas (ESEA) This Year? (Zacks)
09:40AM	Are Finance Stocks Lagging Royal Bank Of Canada (RY) This Year? (Zacks)
09:40AM	Is Great Lakes Dredge & Dock (GLDD) Outperforming Other Construction Stocks This Year? (Zacks)
09:40AM	Is CommVault Systems (CVLT) Stock Outpacing Its Computer and Technology Peers This Year? (Zacks)
09:40AM	Is Agnico Eagle Mines (AEM) Stock Outpacing Its Basic Materials Peers This Year? (Zacks)
09:40AM	Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? (Zacks)
09:40AM	Are Industrial Products Stocks Lagging Allegion (ALLE) This Year? (Zacks)
Jun-12-25 04:05PM	DBV Technologies to Participate in Upcoming EAACI Congress 2025 (GlobeNewswire) +11.12% -6.09%
Jun-11-25 04:30PM	DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting (GlobeNewswire)
Jun-04-25 04:32PM	Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025 (GlobeNewswire) +5.04%
Jun-03-25 04:30PM	DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document (GlobeNewswire)
May-21-25 09:40AM	Are Medical Stocks Lagging DBV Technologies (DBVT) This Year? (Zacks)
May-16-25 12:00PM	Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A. (DBVT) is a Great Choice (Zacks)
08:50AM	DBV Technologies (DBVT) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-15-25 04:30PM	Combined General Meeting of June 11, 2025 (GlobeNewswire)
May-06-25 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025 (GlobeNewswire)
May-05-25 04:30PM	DBV Technologies to Participate in the Citizens JMP Life Sciences Conference (GlobeNewswire)
Apr-30-25 04:00PM	DBV Technologies Reports First Quarter 2025 Financial Results (GlobeNewswire)
08:50AM	Here's Why Momentum in DBV Technologies (DBVT) Should Keep going (Zacks)
06:25AM	Why DBV Technologies S.A. (DBVT) is Surging in 2025 (Insider Monkey)
Apr-14-25 08:50AM	Here's What Could Help DBV Technologies (DBVT) Maintain Its Recent Price Strength (Zacks) +6.42%
Apr-11-25 04:30PM	DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document (GlobeNewswire)
Apr-10-25 07:00AM	3 Biopharmaceutical Stocks Bucking the Sell-Off (MarketBeat)
Mar-27-25 10:30PM	DBV Technologies Announces Financing of up to $306.9 Million ( 284.5 Million) to Advance Viaskin Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved (GlobeNewswire) +58.57%
Mar-24-25 03:09AM	DBV Now Plans BLA Submission For Viaskin Peanut Patch In Children 4 - 7-years-old In H1, 2026 (RTT News) -10.62%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mohideen Pharis	Chief Medical Officer	Jul 29 '26	Sale	2.70	464	1,253	144,531	Jul 31 04:15 PM
Mohideen Pharis	Chief Medical Officer	Jan 29 '26	Sale	4.86	534	2,595	144,995	Feb 02 04:30 PM
EPIC Bpifrance	Member of 10% owner group	Dec 17 '25	Sale	4.85	2,076,990	10,070,232	8,595,472	Dec 19 04:04 PM
EPIC Bpifrance	Member of 10% owner group	Dec 18 '25	Sale	4.19	1,292,103	5,413,912	7,303,369	Dec 19 04:04 PM
Mohideen Pharis	Chief Medical Officer	Nov 20 '25	Sale	2.88	6,496	18,708	103,153	Nov 25 04:15 PM
Mohideen Pharis	Chief Medical Officer	Nov 21 '25	Sale	2.77	1,624	4,498	101,529	Nov 25 04:15 PM

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.

CEO & DirectorMr. Daniel Tasse

Chief Financial OfficerMs. Virginie Simone Jeanine Verrechia Boucinha M.B.A.

Chief Medical OfficerDr. Pharis Mohideen M.D.

Ph.D.Dr. Kevin P. Malobisky M.S.

VP & Head of Investor RelationsMr. Jonathan Neely

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DBVT

DBV Technologies ADR

Upgrade your Finviz experience